Parkinson's disease: from brain homogenate to treatment.
D000818:Animals; D001921:Brain / Q000201:enzymology / Q000378:metabolism*; D002421:Caudate Nucleus / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005917:Globus Pallidus / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D008750:Methyldopa / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism; D010648:Phenylacetates / Q000378:metabolism; D011955:Receptors, Drug; D013378:Substantia Nigra / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D010648:Phenylacetates; D011955:Receptors, Drug; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D014446:Tyrosine 3-Monooxygenase; D004296:Dopa Decarboxylase; D004298:Dopamine; D006719:Homovanillic Acid